Fecal calprotectin (FC) is extensively used in Gastroenterology practice as a noninvasive marker to differentiate between inflammatory bowel disease (IBD) and functional disorders. It has been found to be useful in noninvasively assessing mucosal healing, monitoring treatment and predicting relapse, though, the optimal cut-offs are yet unclear. FC may help in predicting the postoperative recurrence and pouchitis. The role of FC in other colonic disorders is unclear and needs to be explored further. The present review highlights the literature regarding the use of FC in the management of IBD.